Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD and Safety of Intravenous Tocilizumab in Giant Cell Arteritis
NCT03923738Phase 1Completed
- Sponsor
- Roche
- Start
- Aug 2019
- Primary completion
- Nov 2020
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label trial of tocilizumab in giant cell arteritis (GCA), sponsored by Roche. Primary endpoints: Maximum Serum Concentration at Week 24, Trough Serum Concentration at Week 24 and 2 more. Started Aug 2019; status: completed.
02
Drugs
tocilizumab
03
Conditions
giant cell arteritis (GCA)
Beyond the preview
Go deeper on NCT03923738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03923738.